Process for alkoxyalkylating a 3-hydroxy group in 13-alkylgona-(and 8-isogona)-1,3,5(10)trienes and delta-6-,delta-7-,delta-8(9)-,delta-9(11)-,and delta - 6,8(9) - dehydro derivatives thereof

ABSTRACT

3-(ALKOXYMETHOXY)-13-ALKYLGONA(AND 8-2SOGONA)-1,3,5(10)-TRIENES AND $6-, $7-, $8(9)-, $9(11)- AND $6,8(9)-DEHYDRO ANALOGS THEREOF ARE PREPARED BY ALKYLATING AN ACTIVE METAL DERIVATIVE OF A 3-HYDROXYL GROUP IN THE CORRESPONDING A-RING AROMTIC STEROID WITH A (LOWER) ALKYL HALOMETHYL ETHER. THE PRODUCTS OF THE PROCESS ARE HORMONALLY ACTIVE, ESPECIALLY ESTROGENICALLY AND ANTI-LIPEMICALLY AND ARE ALSO USEFUL AS INTERMEDIATES IN THE PREPARATION OF HORMONALLY ACTIVE STEROIDS.

United States Patent 3,555,054 PROCESS FOR ALKOXYALKYLATING A 3-HY- DROXY GROUP IN 13-ALKYLGONA-(AND 8- ISOGONA)-1,3,5()TRIENES AND DELTA-6-, DELTA-7-, DELTA-8(9)-, DELTA-9(11)-, AND DELTA 6,8(9) DEHYDRO DERIVATIVES THEREOF Harshavadan C. Shah, Philadelphia, Reinhardt P. Stein,

Conshohocken, and Herchel Smith, Wayne, Pa., assignors to American Home Products Corporation, New York, N.Y., a corporation of Delaware No Drawing. Continuation-impart of application Ser. No. 814,446, Apr. 8, 1969. This application May 19, 1969, Ser. No. 825,948

Int. Cl. C07c 169/08 U.S. Cl. 260-397.4 22 Claims ABSTRACT OF THE DISCLOSURE 3-(alkoxymethoxy)-l3-alkylgona(and 8-isogona)-1,3,5- (10)-trienes and A A"-, A A and N -dehydro analogs thereof are prepared by alkylating an active metal derivative of a 3-hydroxyl group in the corresponding A-ring aromatic steroid with a (lower)alkyl halomethyl ether. The products of the process are hormonally active, especially estrogenically and anti-lipemically and are also useful as intermediates in the preparation of hormonally active steroids.

This application is a continuation-in-part of copending application Ser. No. 814,446 filed on Apr. 8, 1969 and now abandoned.

This invention is concerned with the preparation of steroid compounds useful in therapy and as intermediates for therapeutically-useful compounds. More particularly, it relates to a new and useful process to introduce an alkoxymethoxy group into the 3-position of A-ring aromatic steroids. Compounds prepared by this process are estrogenicallyand anti-lipemically-active and are important intermediates in the preparation of biologically active steroids,

BACKGROUND OF THE INVENTION It has been found that important therapeutic activity and value as intermediates are possessed by a family of A-ring aromatic steroids which optionally contain double bonds at the 6-, 7-, 8(9)-, 9(11)-, and 6,8(9)-positions, if the 3-position bears a (lower) alkoxymethoxy substituent, preferably a methoxymethoxy group. Moreover, the biological activity of such 3-alkoxymethoxy compounds is considerably different from the corresponding 3-alkoxy and 3-hydroxy steroids, in that oral estrogenic activity is of increased duration and the antilipemic activity is strongly increased. Furthermore, means often are required to protect the 3-hydr0xyl group of an A-ring aromatic steroid in order to transform other groups in the steroid molecule, under basic or neutral conditions, and then to regenerate the hydroxyl group and, because of its ready cleavage by acid hydrolysis, the 3-a1koxymethoxy group is well-suited for such a protective function. Unfortunately, because of this acid-lability, it is not convenient to prepare 3-(lower)alkoxy-methoxy A-ring-substituted aromatic steroids by methods which are useful to make the corresponding A-ring substituted S-ethers. For example, total synthesis from a suitably substituted a-tetralone according to UK. Pat. No. 1,041,275 would not be convenient (although it is very useful for the corresponding hydroxy and alkoxy substituted compounds) because acidsensitive groups are hydrolyzed when the 8(14)-s,ecogonane (tetralone-condensate) is cyclodehydrated to the gonapentaenone under the conventional acidic conditions.

3,555,054 Patented Jan. 12, 1971 ICC It would therefore be of substantial benefit to provide a simple method to prepare such valuable compounds which are inaccessible by the usual methods. Such a means would permit, for example, the easy preparation of d-3-(meth0xymethoXy)estra-1,3,5(l0)-trien-17-one and the corresponding -01, which have strongly enhanced antilipemic properties in comparison with prior art compounds. It has now surprisingly been found that, with the use of a dry metal salt of the A-ring aromatic steroid as a reagent and careful selection of reaction conditions such an alkoxymethylation can be accomplished to provide these acid-labile products and intermediates.

It is, accordingly, a primary object of this invention to provide a means to alkoxymethylate an A-ring hydroxyl group in A-ring aromatic steroids.

It is a further object to provide a means to protect an A-ring hydroxyl group in A-ring aromatic steroids during subsequent transformations under basic and neutral conditions.

It is another object of the instant invention to provide meas to obtain A-ring alkoxymethoxylated, A-ring aromatic steroids useful for their estrogenic and anti-lipemic properties.

It is a further object of this invention to provide a means to obtain A-ring alkoxymethoxylated, A-ring aromatic steroids with prolonged estrogenic activity after oral administration and with enhanced anti-lipemic activity.

DESCRIPTION OF THE INVENTION These and other objects of this invention are readily obtained by practice of the instant method which is, in essence: a process for the preparation of a 3-(lower) alkoxy(lower)alkoxy-13-alkyl gona (or -8-isogona)-1,3,5- (l0)-triene compound of the formula and the A A A A and the A dehydro analogs thereof, wherein R and R are (lower)alkyl, X is R is (lower)alkyl, (lower)alkenyl, (lower)alkynyl or halo (lower)alkynyl;

Y is methylene or hydroxymethylene, the symbol (2) indicates a, or B-configuration, and the broken lines indicate unsaturation in said analogs, which comprises alkylating in an aprotic medium a corresponding aromatic steroidal salt of the formula wherein R, X and Y are as defined above and M is an ion derived from an alkali metal or an alkaline earth metal, with a (loWer)-alkyl halomethyl ether of the formula wherein hal is chloro, bromo, iodo or fluoro, until formation of the 3-(lower)alkoxy(lower)alkoxy group is substantially complete.

Special mention is made of a number of important embodiments of the instant invention.

These are respectively:

A process as next above defined wherein said (lower) alkyl halomethyl ether is chloromethyl methyl ether.

A process as first above defined wherein said R substituent is polycarbon(lower)alkyl. This provides an especially useful family of steroids with a valuable separation in hormonal properties not possessed by those in which R is methyl.

A process as first above defined wherein said aprotic medium is selected from chloroform, tetrahydrofuran, benzene, dioxane, dimethylformarnide, dimethylsulfoxide or 1,2-dimethoxyethane.

A process as first above defined wherein the alkylation is carried out at a temperature of from about 20 C. to about 100 C. for from about 2 hours to about 48 hours.

A process as first above defined wherein d-3-(methoxymethoxy)estra-1,3,5(10)-trien-17-one is prepared by alkylating the sodium salt of d-estrone in chloroform with chloromethyl methyl ether; the embodiment thereof including the step of ethynylating d-3-(methoxymethoxy) estra-l,3,5(10)-trien-17-one to produce d-3-(methoxymethoxy)-17a-ethynylestra-1,3,5(10)-trien-l7B-ol; and the embodiment thereof including the step of reducing d-3- (methoxymethoxy)estra-1,3,5(10)-trien-17-one to produce d-B-(methoxymethoxy)estra-l,3,5( 10 trien-l7 8-ol.

A process as first above defined wherein dl-l3-ethyl-3- methoxymethoxy)gona-1,3,5 10)-trien-17-one is prepared by alkylating the sodium salt of dl-13-ethyl-3-hydroxygona-1,3,5(10) trien-17-one in tetrahydrofuran with chloromethyl methyl ether; the embodiment thereof including the step of ethynylating dl-13-ethyl-3-(methoxymethoxy)gona-l,3,5(10)-trien-l7-one to produce dl-13- ethyl 3 (methoxymethoxy) 17a ethynylgona 1,3,5 (10)-trien-17fl-ol; and the embodiment thereof including the step of reducing dl-l3-ethyl-3-(methoxymethoxy) gona-l,3,5(10)-trien-l7-one to produce dl-l3-ethyl-3- (methoxymethoxy)gona-1,3,5(10)-trien-l7fi-ol.

A process as first above defined wherein dl-3-(methoxymethoxy)estra-l,3,5(l),8-tetraen-l7-one is prepared by alkylating the sodium salt of dl-3-hydroxyestra-1,3,5(10), 8-tetraen-l7-one in tetrahydrofuran with chloromethyl methyl ether; and the embodiment thereof including the step of ethynylating dl-3-(methoxymethoxy)estra-1,3,5 (),8-tetraen17-one to produce dl-3-(methoxymethoxy) l7a-ethynylestra-l,3,5 (10) ,8-tetraen-l7fi-ol.

A process as first above defined wherein dl-l3-ethyl-3- (methoxymethoxy) 8a gona 1,3,5(l0) trien 17- one is prepared by alkylating the sodium salt of dl-l3- ethyl 3 hydroxy 80c gona 1,3,5(10) trien 17- one in tetrahydrofuran with chloromethyl methyl ether; and the embodiment thereof including the step of ethynylating dl l3 ethyl 3 (methoxymethoxy) 8a gona- 1,3,5 10)-trien-l7-one to produce dl-l3-ethyl-3-(methoxymethoxy)-17a-ethynyl-8a-gona-l,3,5 10)-trien-l7fi-ol.

A process as first above defined wherein d-3-(methoxymethoxy)-estra-1,3,5(10),8-tetraen-17-one is prepared by alkylating the sodium salt of d-3-hydroxyestra-1,3,5(10), 8-tetraen-17-one in tetrahydrofuran with chloromethyl methyl ether; and the embodiment thereof including the step of ethynylating d-3-(methoxymethoxy)estra-l,3,5 (l0),8-tetraen-l7-one to produce d-3-methoxymethoxy)- 17a-ethynylestra-1,3,5 10) ,8-tetraen-17B-ol.

A process as first above defined wherein d-3-(methoxymethoxy)-8u-estra-l,3,5(10)-trien-17-one is prepared by alkylating the sodium salt of d-3-hydroxy-8a-estra-1,3,5

(10)-trien-17-one in chloroform with chloromethyl methyl ether; and the embodiment thereof including the step of ethynylating d 3 (methoxyrnethoxy) c estra- 1,3,5 (10)-trien-l7-one to produce d-l7a-ethynyl-3-(methoxymethoxy)-8ot-estra-l,3,5(10)-trien-l7fl-ol.

A process as first above defined wherein d-13-ethyl-3- (methoxymethoxy) 80c gona 1,3,5(10) trien-l7- one is prepared by alkylating the sodium salt of d-l3- ethyl 3 hydroxy 8a gona 1,3,5(l0) trien-l7- one in tetrahydrofuran with chloromethyl methyl ether; and the embodiment thereof including the step of ethynylating d l3 ethyl 3 (methoxymethoxy) 8a gona- 1,3,5 (10)-trien-17-one to produce d-l3-ethyl-17a-ethynyl- 3 (methoxymethoxy) 80c gona 1,3,5 (10) trienl7/3-ol; and the embodiment thereof including the step of methylating d 13 ethyl 3 (methoxymethoxy) 8agona-l,3,5(10)-trien-l7-one to produce d-l3-ethyl-3-(methoxymethoxy) 17oz methyl 80c gona l,3,5(l0)- trien-l7fi-ol.

In the specification and in the appended claims the term (lower)alkyl contemplates saturated hydrocarbon radicals, straight and branched chain, having from about 1 to about 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, n-hexyl, 3-methylpentyl and the like. The term polycarbon (lower)alkyl contemplates groups containing from about 2 to about 6 carbon atoms, as illustrated for (lower)alkyl above, but excludes, of course, methyl. The term (lower) alkenyl contemplates mono-olefinic polycarbon(lower) alkyl groups, preferably those in which the unsaturation is mto the point of attachment to the steroid ring, and especially preferably, the vinyl group. The term (lower) alkynyl contemplates polycarbon(lower)alkyl groups containing one carbon-to-carbon triple bond, preferably those in which the unsaturation is ato the point of attachment to the steroid ring, and especially preferably the ethynyl group. The term halo(lower)alkynyl contemplates (lower)alkynyl groups mono-substituted with chloro, fluoro, bromo or iodo, preferably the chloroethynyl group. The term alkali metal contemplates active metals of the family of monovalent elements of the first group of the periodic system, e.g., Li, Na, K, Rb, and Cs. Preferred alkali metals are lithium, sodium and potassium, especially preferred is sodium. The term alkaline earth metal contemplates active metals of the family of divalent elements of the second group of the periodic system, e.g., magnesium and calcium. The term (lower)alkoxy (lower) alkoxy contemplates in its broadest aspects substituents of the formula: R OCH(R )O, wherein R is as above defined and R is hydrogen or methyl; (lower)alkoxymethoxy is preferred, and methoxymethoxy is especially preferred.

The aromatic steroidal salts used as starting materials herein can be prepared by techniques known to those skilled in the art. For example, the corresponding 3-hydroxy A-ring aromatic steroid is reacted with an alkali metalor alkaline earth metal alkoxide in an alcohol, preferably, for example with sodium methoxide in methanol followed by complete removal of the alcohol, for example, by distillation under reduced pressure to provide the dry aromatic steroidal salt. These techniques Will be illustrated in detail hereinafter. The required 3-hydroxy A-ring aromatic steroids are commercially available or can be prepared by techniques known to those skilled in the art. For example, d-estrone (R is CH X is C=O, Y is methylene, 8/3-H) is an item of commerce. The corresponding 13-alkylgona l,3,5-(l0)-trien-3-ols (and the 16-hydroxy analogs thereof) are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in copending US. patent application, Ser. No. 534,353, filed Mar 15, 1966.

d(+)-estra-l,3,5(10),7-tetraene-3,l7fl-diol, also known as d(+)-l7fi-dihydro equilin (a 7-dehydro analog wherein R is methyl, X is hydroxymethylene and Y is methylene) and related compounds are prepared by methods exemplified by R. P. Stein, G. C. Buzby, Jr., and Herchel Smith in copending U.S. patent application Ser. No. 760,- 212 filed Sept. 16, 1968.

The 13-alkyl-8-isogona 1,3,5 (l)-trien-3-ols are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in U.S. Pat. No. 3,407,217.

The l3-alkylgona-l,3,5(l-0),8(9)-tetraen-3-ols are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in U.S. Pat. No. 3,391,169.

The 13-alkylgona-l,3,5(l0),9(ll)-tetraen-3-ols are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in U.S. 3,391,170.

The 13-alkylgona-1,3,5(10),8-tetraen-3-ols are prepared by means exemplified in British Pats. 991,594 and 1,024,- 911.

The 13-alkylgona 1,3,5 ),6,8(9),pentaen-3-ols are prepared by means exemplified by R. P. Stein, R. C. Smith and H. Smith in copending U.S. patent application Ser. No. 647,910, filed June 22, 1967, now U.S. Pat. No. 3,475,468 of Oct. 28, 1969.

The 13-alkylgona-1,3,5(10),6-tetraen-3-ols can be prepared from the 3-methoxy-l3-alkylgona-1,3,5(10)-trienes of Ser. No. 534,353, filed Mar. 15, 1966 by introducing a 6-keto group with t-butyl chromate in carbon tetrachloride, reduction to the 6-01 with a hydride, such as sodium borohydride, and dehydrating, as with POCl in dimethylformamide, or p-toluenesulfonic acid (or iodine) in refluxing benzene to introduce the double bond between C and 0;, according to procedures such as those described in G. C. Buzby, Jr., G. H. Douglas, C. R. Walk and H. Smith, Excerpta Medica Int. Cong. Series No. 132 Proceedings of the Second Int. Congress on Hormonal Steroids, Milan, May 1966, p. 311; then cleaving the 3-methoxy group in a known way, e.g., by refluxing with pyridine hydrochloride or by cleavage with a Grignard reagent according to R. P. Stein, G. C. Buzby, Jr. and H. Smith, copending U.S. patent application, Ser. No. 694,036, filed Dec. 28, 1967, now U.S. Pat. No. 3,436,411 of Apr. 1, 1969.

Introduction of the 161- or B-hydroxy group can be accomplished in known ways. For example, the substrates are oximated in the presence of an alkyl nitrite and the l6-oximino compound is hydrolyzed, for instance by reduction with zinc and a lower alkanoic acid to give a 16-ketone. This can be reduced to the 16a-o1 for instance with an alkali metal and lower alkanol or by catalytic hydrogenation to give the 16/3-01. These methods are exemplified in UK. 1,115,954.

The (lower)alkyl halomethyl others are available or can be prepared by means known to those skilled in the art. For instance, chloromethyl methyl ether is an item of commerce and can be prepared by reacting paraformaldehyde, methanol and hydrogen chloride. The other ethers are rescribed in the literature, e.g., bromomethyl methyl ether, C.A. 47: 9294a; fluoromethyl methyl ether C.A. 50: 13716d; iodomethyl methyl ether, C.A. 47: 9294b; chloromethyl ethyl ether, C.A. 47: 3223d; chloromethyl propyl ether, C.A. 46: 10096f; and bromomethyl isopentyl ether, C.A. 43: 2926c.

The term aprotic medium when used herein is contemplated in its broadest sense. That is it includes diluents and suspending agents which are inert, i.e., incapable of reacting with either reactive reagent, i.e., the dry aromatic steroidal salt or the (lower)alky1 halomethyl ether. Those skilled in the art will immediately recognize that the term includes hydrocarbons, aliphatic, such as hexane, heptane, and the like, as well as aromatic, such as benzene, toluene, xylene, and the like; together with ethers, such as isopropyl ether, isobutyl ether, 1,2-dimethoxyethane, tetrahydrofuran, dioxane, and the like, chlorinated hydrocarbons, such as methylene chloride, chloroform, ethylene dichloride, and the like; sulfoxides, such as dialkylsulfoxides; and amides, such as dialkylamides. Excluded, of course, would be alcohols, acids, water, amines and other protonic media. Preferred aprotic media are chloroform,

6 tetrahydrofuran, benzene, dioxane, dimethylformamide, dimethylsulfoxide and 1,2-dimethoxyethane.

In carrying out the instant process, the aromatic steroidal salt is alkylated in an aprotic medium with the (lower) alkyl halomethyl ether at a temperature ranging from somewhat below room temperatures to somewhat elevated temperatures until alkylation is substantially complete, followed by a conventional isolation procedure to obtain on work-up the corresponding alkoxymethoxy A-ring aromatic product. Even if X and/ or Y are hydroxymethylene in the substrate, under the conditions to be described, very little tendency is observed for any reaction between non-aromatic hydroxy] groups and the alkoxy halomethyl ether reagent. The temperature at which the alkylation is carried out is at least high enough to permit completion of the reaction in a reasonable length of time, but not so high as to permit side reactions or decomposition of the reagents or products. The preferred temperature range is from about 20 C. to about C. and this provides complete reaction in times ranging from about 2 hours to about 48 hours. In one convenient manner of proceeding, the aromatic steroidal salt is suspended in from about 10 to about 50 parts by volume of the aprotic medium per part by weight of steroid and treated with a solution the alkoxy halomethyl ether (an excess can be used) in about 5 parts by volume of an aprotic solvent per part by weight of alkoxy halomethyl ether. The mixture is allowed to stand until the reaction is substantially completefor example, with most substrates, the mixture can be kept at room temperature (about 23 C.) for about 12 hours and alkylation is complete. The product is recovered by any conventional means. One useful general process is to extract the reaction mixture with an aqueous base (e.g., 1 N KOH), if a Water-immiscible aprotic solvent was used (such as chloroform), then evaporate the dried, extracted reaction mixture to dryness. This leaves the product as a residue. It can be purified, if desired, by trituration, chromatography and recrystallization, e.g., from a lower alkanol, such as methanol, or from hexane.

As will be obvious to those skilled in the art after reading this disclosure, the basic process will provide 3- (lower)alkoxy-methoxy steroids which can be modified in known ways in subsequent steps to provide transformations at 016 and C-17some of these embodiments will be exemplified in detail hereinafter. For example a 17-keto group can be converted by reduction to a 17,3- hydroxy group or by ketalization with a ketalizing alcohol to a 17-ketal. If desired, a 17-keto group can be converted to a 17a-alkyl-, alkenyl-, alkynyl, or haloalknyl- -01 group in known ways. And again, if desired, a 16-methylene group will be converted to a 16-hydroxymethylene group. The invention also contemplates the basic process including such subsequent steps of converting the intermediate 3-(lower)alkoxymethoxysteroid to the products when carried out separately.

The time and temperature ranges used in describing the aforementioned process steps simply represent the most convenient ranges consistent with carrying out the reaction in a minimum of time without undue difficulty. Thus, reaction temperatures appreciably below these can be used, but their use considerably extends the reaction time. Similiarly, reaction temperatures higher than those mentioned can be employed with a concomitant decrease in reaction time, although purity of the product may be somewhat decreased.

The sources for the starting material have been specified hereinabove. Generally, all can be prepared by totally synthetic processes described by Douglas, Graves, Hartley, Hughes, McLoughlin, Siddall and Smith in I Chem. Soc., 1963 pages 5077-94.

In the product of a total synthesis which has not included a suitable resolution stage the compounds prepared by the invention will be present as racemates.

Using a convention approved by Fieser and Fieser, Steroids, p. 336 (1959), the compounds designated as the d-forms are the enantiomers corresponding in configuration at C-13 to that of the natural hormone estrone. The corresponding enantiomorphs are consequently designated the l-forms and the racemates the dlforms. Racemates will be depicted by structural formulas which show only the enantiomorphs of the d-configuration.

As is mentioned hereinabove, the compounds prepared by this process have estrogenic and anti-lipemic activity. This makes them useful to treat conditions in mammals responsive to treatment with estrogenic drugs, such as for example, menopause, senile vaginitis, kraurosis vulvae, pruritis vulvae and the like. In addition they are useful to lower blood lipid level of mammals and can be used whenever anti-lipemic agents are indicated, such as in the treatment of various hyperlipaemias or where the incidence of atherosclerosis is to be minimized. The products prepared by the instant process are also useful as intermediates for the preparation of other steroids, which have hormonal or other useful activities.

The products of Formula I prepared by this invention can be used in association with a pharmaceutically acceptable carrier. They can be formulated in liquid or solid forms, for instance as capsules, tablets, suppositories, powders, dispersible granules, cachets, and the like by combining them with conventional carriers. Such conventional carriers include magnesium carbonate, or

stearate talc, sugar, lactose, pectin, dextrin, starch, gela- 3 tin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose low melting wax or cocoa butter. Diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet-disintegrating agents can be used.

Powders or tablets preferably contain 5 or to 99% of x the active constituent. The active steroid can be formulated with an encapsulating material with or without other carriers.

Liquid preparations such as solutions, suspensions or emulsions can also be used. Such preparations include dispersions in a pharmaceutically acceptable carrier such as arachis oil or sterile water, preferably containing a noniouic surface active agent such as fattly acid esters of polyhydroxy compounds, e.g., sorbitan, aqueous starch in sodium carboxymethylcellulose solutions, aqueous propylene glycol or polyethylene glycol. Thus a water-propylene glycol solution can be used for parenteral injection and aqueous suspensions suitable for oral use can be made by utilizing natural or synthetic gums, resins, methyl cellulose or other well known suspending agents.

The composition can be in unit dose form in which the dose unit is for instance from about 0.1 to about 200 mg. of each active steroid. The unit dose form can be a packaged composition, e.g., packeted powder, vials or ampules or, for example, in the form of capsules, cachets or tablets or any number of these in packaged form. The pharmaceutical compositions can also consist substantially solely of the active steroid when this is in unit dose form. When used for the purposes stated above, the dosage of the compounds will vary with the condition being treated, but a good starting dosage in general will be in the range established for estradiol (Merck-Index Seventh Edition, p. 416 (1960)).

Merely by way of illustration, in a standard anti-lipemic assay in male weanling rats of about 100 g. mean body weight fed on a hypercholesterolemic diet for three weeks, d-3-(methoxymethoxy)-l7a-ethynylestra-1,3,5(10)-trien- 17B-ol demonstrated significant lowering of the serum cholesterol level following administration of 0.2 mg. perorally.

Of course, as will be clear to those skilled in the art, in addition to substrates designated by the formula above, the process broadly can be applied to obvious chemical equivalents thereof but differing therefrom in the sense of having other functional groups attached tothe steroid nucleus, whenever such groups do not themselves interfere or become affected by the process, unless, in exceptional instances, this is a desired effect. Similarly, the steroid nucleus may contain any substitution at positions other than at 16 or 17, as, for example, 6-methyl. Broadly stated, therefore, useful substrates would be depresentwherein M is an ion derived from an alkali metal or an alkaline earth metal and R is a cyclopentanopolyhydrophenanthrene nucleus, with an aromatic A-ring monosubstituted by OM and which, on alkoxymethylation of the OM group, would provide a product with antilipemic and estrogenic activity.

DESCRIPTION OF THE PREFERRED EMBODIMENTS The following examples are given by way of illustration and are not to be construed as limitations of this invention, variations of which are possible without departing from the scope and spirit thereof.

EXAMPLE 1 d- 3 (methoxymethoxy estral ,3,5-( 10 trienl 7-one To a stirred solution of 0.6 g. of sodium methoxide in methanol (20 ml.), and 3.0 g. of d-estrone, at about 23 C., over a period of ten minutes, then stir for minutes. Remove the solvent in vacuo. Triturate the residue in ether, filter, then suspend the dry sodium salt in chloroform (15 ml.). Add a solution of 0.9 g. of chloromethymethyl ether in chloroform (5 ml.), and let stand at about 23 C. overnight. Extract the chloroform with 1 N KOH then wash with water. Dry the chloroform over anhydrous sodium sulfate, filter and remove the chloroform in vacuo. Triturate the residue with benzene (30 ml.) and filter through a column of fluorosilicate. Remove the solvent in vacuo to give a clear oil. Recrystallize from methanol to give 1.3 g. of the title product. Further purify a sample by recrystallization from methanol to give an analytical sample, M.P. 97-98 C. [a] :+137 (c.=l, CHCl Analysis.Calcd. for C H O (percent): C, 76.40; H, 8.34. Found (percent): C, 76.12; H, 8.34.

EXAMPLE 2 Suspend 2.0 g. of d-3-(methoxymethoxy)estra-1,3,5 (l0)-trien-l7-one in dimethylsulfoxide (DMSO, ml.) in a 3 necked flask equipped with drying tube, magnetic stirrer and a gas inlet. Saturate with acetylene by bubbling the dry gas through the suspension for 1 hour. Add two aliquots (of 1.0 g. each) of lithium acetylide-ethylenediamine complex 1 /2 hours apart. Continue stirring under acetylene a further 1% hours then pour the brown mixture into ice water and let stand for 1 hour. Filter the resulting solid and dissolve in CH Cl treat with decolorizing charcoal, filter and remove the solvent in vacuo. tRecrystallize the residue from methanol (cold). Obtain an analytical sample by recrystallization from hexane, to get 1.1 g. of the title compound, M.P. 96100 C.

max.

[a] =+3 (c.=l, CHCIg).

Analysis.Calcd. for C H O (percent): C, 77.61; H, 8.29. Found (percent): C, 77.33; H, 8.21.

EXAMPLE 3 d-3-(methoxyrnethoxy)estra-1,3,5( 10) trien-17fl-ol Dissolve 1.8 g. of d-3-(methoxymethoxy)estra 1,3,5 l0)-trien-l7-one in methanol (30 ml.) then add in small aliquots to the stirred solution, 1.0 g. of sodium borohydride over a period of 30 minutes. Leave the mixture at about 23 C. for about 16 hours. Add another 1.0 g. of sodium borohydride and stir for 1 hour. Add water (200 ml.) dropwise to the stirred mixture. Filter and dry the white solid then suspend the product in benzene and filter through a column of fluosilicate. Remove the solvent in vacuo. Filter the residue in ether through a cotton plug, evaporate the ether and pump it dry into a glass (1.25 g.). [u] |=-|67 (c.=1, CHCl Analysis.Calcd. for C H O (percent): C, 75.91; H, 8.92. Found (percent): C, 75.45; H, 8.97.

EXAMPLE 4 dl- 13-ethyl-3- (methoxymethoxy -gona- 1,3,5 10) trien-17-one To a stirred solution of 1.4 g. of sodium methoxide in methanol (40 ml.) add 6.0 g. of dl-13-ethyl-3-hydroxygona-1,3,5(10)-trien-17-one over a period of 20 min. then stir 15 minutes more. Remove the solvent in vacuo, triturate the residue in ether and filter. Suspend the dry sodium salt in tetrahydrofuran (THF, 35 ml.). Add to it, a solution of chloromethylmethyl ether (2 ml.) in THF (10 86 C. Obtain an analytical sample by recrystallization ml.). Let the mixture stand at about 23 C. for 24 hours. Remove the solvent in vacuo. Suspend the residue in benzene and filter through a column of fluosilicate. Remove the solvent in vacuo. crystallize the residue by cooling in cold acetone to give 3.8 g. of title product, M.P. 80- 86 C. Obtain an analytical sample by recrystallization from methanol to give the title product, M.P. 8489 C.

EXAMPLE 5 mun dl-13-ethyl-3-(methoxymethoxy) -17a-ethynylgona- 1,3,5 -trien-17fi-ol Suspend 2.3 g. of dl-13-ethyl-3-(methoxymethoxy) gona-1,3,5(10)-trien-17-one in DMSO (30 ml.) in a 3 necked flask equipped with drying tube, magnetic stirrer, and a gas inlet. Saturate the suspension with acetylene by bubbling the dry gas through the suspension for 1 hour. Add two aliquots (1.25 g. each) of lithium acetylideethylene diamine complex 1 /2 hr. apart and stir a further 1 /2 hour. Pour the brown mixture into ice-water and let stand for 1 hour. Extract the mixture with ethyl acetate. Remove the solvent in vacuo and dissolve the residue in benzene then filter through a column of fluosilicate. Remove the solvent in vacuo. Dissolve the residue in ether dilute with hexane, cool and let stand to crystallize. Filter to obtain 0.5 g. of title product, M.P. 82-86 C.

ASK: u

EXAMPLE 6 dl-13-ethyl-3-(methoxymethoxy)-gona-1,3,5(10)- trien-17fl-ol Dissolve dl-l3-ethyl-3-(methoxymethoxy) gona 1,3,5 (10)-trien-17-one in methanol (30 ml.). Add in small aliquots to the stirred solution, 1.0 g. of sodium borohydride over a period of 30 minutes. Leave the mixture at about 23 C. overnight. Add another 1.0 g. of sodium borohydride, stir 1 hour then add water (200 ml.) dropwise to the stirred mixture. Extract with ethyl acetate, remove the solvent from the dry extract in vacuo. Dissolve the residue in ether and filter the solution through 10 a cotton plug. Evaporate the ether and pump it dry into a glass to give 1.04 g. of the title product,

A535: 3.0M Analysis.-Calcd. for C H O (percent): C, 76.32; H, 9.15. Found (percent): C, 76.42; H, 8.82.

EXAMPLE 7 dl-3-methoxymethoxy)estra-1,3,5-(10) -8-tetraen-17-one Add slowly, 2.95 g. of dl-3-hydroxyestra-1,3,5(10)-8- tetraen-17-one to a stirred solution of sodium methoxide (0.6 g.) in methanol (30 ml.). Stir an additional /2 hr. then remove the methanol in vacuo. Suspend the dry salt in 25 ml. of THF, then add a solution of chloromethyl methyl ether (0.9 ml.) in THF (5 ml.). Allow the mixture to stand at about 23 C. for 24 hours. Filter the insoluble material, remove the THF in vacuo and triturate the residue with benzene. Filter the suspension through a column of fluosilicate and remove the solvent in vacuo. Recrystallize the residue from methanol to get the pure title product (0.55 g.), M.P. 103-107 C.

x 333; 5.79 26sm,. e14,5000

Analysis.Calcd. for C H O (percent): C, 76.89; H, 7.74. Found (percent): C, 77.19; H, 7.66.

EXAMPLE 8 a'l-3-(methoxymethoxy) 17u-ethynylestra-1,3,5(10),8- tetraen-l7/3-ol Dissolve 1.8 g. of dl-3-(methoxymethoxy)estra-1,3,5 (10),8-tetraen-17-one in DMSO (30 ml.) is a 3 necked flask equipped with drying tube, magnetic stirrer and a gas inlet. Saturate the suspension with acetylene gas by bubbling in the dry gas for 1 hour. Add two aliquots (of 1.25 g. each) of lithium acetylide-ethylene diamine complex 1 /2 hour apart, then stir a further 1 /2 hour. Pour the mixture into ice water. Extract the mixture with ether and evaporate the dry extract in vacuo. Dissolve the residue in ether, filter through a cotton plug then evaporate the ether. Pump the residue to a glass to obtain 400 mg. of title product,

EtOH Mm.

AKBL

EXAMPLE 9 Add sodium methoxide (0.7 g.) to anhydrous methanol (20 ml.). To the stirred solution add dl-l3-ethyl-3-hydroxy-8a-gona-1,3,5(10)-trien-17-one (3.0 g.) stir an additional ten minutes after complete addition. Remove the solvent in vacuo, triturate the residue with ether and remove the ether in vacuo. To the dry residue add THF (35 ml.) followed by THF (10 ml.) containing chloromethylmethyl ether (1.0 ml.). Allow the mixture to stand at room temperature for 24 hours. Filter, remove the solvent from the filtrate in vacuo. Dissolve the residue in benzene and filter through a column of fluosilicate. Remove the solvent in vacuo, boil the residue with hexane and filter. Remove the solvent from the filtrate in vacuo, scratch the chilled residue then add methanol and filter to get 1.8 g. of title product, M.P. 56-63 C. Obtain an analytical sample by recrystallization from methanol, M.P. 7074 C.

ARBI- max.

EXAMPLE l1 d-3- (methoxy1nethoxy)estra-1,3,5-( ,8-tetraen-17-one Add dry sodium methoxide (0.6 g.) to anhydrous methanol (40 ml.). To the stirred solution add d-3-hydroxyestra-1,3,5-(10),8-tetraen-17-one (2.4 g.) and slowly stir for an additional /2 hour, then remove the methanol in vacuo. Suspend the dry residue in ml. of THF and add a solution of chloromethylmethyl ether (0.9 ml.) in THF (5 ml.) and let stand at about 23 C. for 24 hours. Filter and remove the solvent in vacuo. Dissolve the residue in benzene and pass through a column of fluosilicate. Remove the solvent in vacuo and crystallize the residue from methanol to give 775 mg. of the title Product.

Prepare an analytical sample by recrystallization from methanol to give the pure product, M.P. 78-80 C.

Mil i. 5.81 276 m (6 8,600)

Analysis.Calcd. for C H O (percent): C, 76.89; H, 7.74. Found (percent): C, 77.20; H, 7.68.

EXAMPLE 12 d-3-(methoxymethoxy)-l7a-ethynyl-estra-l,3,5(10),8-

tetraen-l7fi-ol Dissolve d-3-(methoxymethoxy) estra 1,3,5 (l0),8- tetraen-17-one (625 mg.) in ml. of anhydrous DMSO. Pass dry acetylene gas through the suspension for 1 hour. Add lithium acetylide-ethylene diamine (1.0 g.) in 0.5 g. portions 1 hr. apart. Stir and pass acetylene gas for a further 1% hour then pour the mixture into ice Water and let stand for 1 hour. Extract the mixture with ether. Remove the dry ether in vacuo and dissolve the residue in ether. Filter the extract through a cotton plug. Remove the ether in vacuo and pump the residue to a glass to get 175 mg. of title product,

AKBr.

EXAMPLE 13 The procedure of Example 1 is repeated, substituting for chloromethyl methyl ether, stoichiometrical amounts of the following (lower)alkoxy halomethyl ethers:

The following 3-(lower)alkoxymethoxyestra-l,3,5(10)- trien-17-ones are obtained:

12' EXAMPLE 14 The procedure of Example 1 is repeated substituting for d-estrone, stoichiometrical amounts of the following A- ring aromatic steroids:

g Y I \\I IP HO- B- or C-ring unsatur- R X Y ation CHgCHz /C CH No.

ozorr OII OlIaCIIz C CH2 No.

CHgCHz /C\ CH2 N0.

/OH 01130112 o CH2 No.

C50 Br H CH3CH2 /C CH2 No. CH: CH

CHaCHz o on. No.

cutout CHgClIZ C CH2 N0.

CH2 \C=O CH2 A6- CHaCII: C=O C112 A CIIIQCIIZ C=O ClIz A(").

ClIaCIIZ /C=O CH2 A.

0 11: 01130112 /C a-hydroxymethyleno N o.

OH CHQCHZ /C B-ltydroxymcthylcne No.

01192011 o=o om No.

CH (CH2)4CH1 /C=O CH: No.

13 The following 3-methoxymethoxy-l3-alkylgona-1,3,5 (10)-triene compounds (and dehydro analogs) are obtained:

p Y I i CHaOCHr- I,

Bf-or C- rmg un- R X Y saturation /OH CHaCHz /C\ CH: NO.

/OH CHaCHz /C CH2 NO.

/OH 01130112 /C CH2 NO.

/OH CHBGHz CH2 No.

/OH CHaCHz /C CH2 N0.

/OH CHzCHB 0 CH2 No.

onions (31130112 0 CH2 No.

CHgCHz C=O CH2 A-.

CHaCHz C=O CH2 A CHECHZ =0 CH2 A OH3CH2 C=0 CH 0410 OH CHQCHQ C a-hydroxymethyl- No.

/ eno H 0H' 01130112 0 fl-hydroxymethyl- No.

/ one (CH3)2CH C=O CH2 N0.

CH (CHz)4CHz /C=O CH2 N0.

EXAMPLE 15 The procedure of Example 1 is repeated, substituting for sodium methoxide, stoichiometrical amounts of the following alkali metal and alkaline earth metal methoxides: lithium methoxide, potassium methoxide and calcium methoxide. Substantially the same results are obtained.

EXAMPLE 16 d-17a-ethynyl-3- (methoxymethoxy) -8 a-estra-1,3,5 10) trien-17fi-ol Dissolve d 3 (methoxymethoxy)-8u-estra-1,3,5(10)- trien-l7-one (prepared by alkylating the sodium salt of d-3-hydroxy-8a-estra-1,3,5 (10)-trien 17 one in chloroform with chloromethyl methyl ether, 1.8 g.) in dry dimethyl sulfoxide ml.) and saturate with a stream of dry acetylene with stirring over a period of onehalf hour. Add 3 portions of lithium acetylide ethylene diamine complex (2.0 g.) at hour intervals. After an elapsed time of three hours pour the reaction on ice and extract with ether. Wash dry and evaporate the ether layer and pass the residue in benzene through a short pad of fluosilicate. Completely remove the solvent to provide the product as a gum (1.60 g.);

max.

EXAMPLE 17 d-13-ethyl-17a-ethyny1-3-(methoxymethoxy)-Sargon- 1,3,S(10)-trien-17p-ol Dissolve d-13-ethyl-3-(methoxymethoxy)-8u-gona-1,3, 5(10)-trien-17one (prepared by alkylating the sodium salt of 'd-13-ethyl-3-hydroxy-8a-gona-1,3,5(10)-trien-17- one in tetrahydrofuran with chloromethyl methyl ether, 5.5 g.) in dry dimethylsulfoxide (200 ml.), saturated with dry acetylene and add 3 portions of lithium acetylide ethylene diamine complex 2.5 g. at hour intervals. After stirring for three hours, in a stream of acetylene, pour the reaction mixture on ice, extract with ether and wash, dry and evaporate the ether layer. Pass the residue in 50% benzene-hexane through fluosilicate and crystallize the contents of the eluate with isopropanol-petroleum ether to obtain the product (0.625 g.), M.P. Ill-113 C.;

=67 (c=2, dioxane) Analysis.C H O requires (percent): C, 77.93; H, 8.53. Found (percent): C, 77.89; H, 8.77.

Obtain a second crop from the mother liquors (2.15 g., M.P. 116-18 0.).

EXAMPLE 18 d-l 3-ethyl-3 (methoxymethoxy) -17u-methyl-8agona- 1,3,5 10 -tric11-17}8-0l Dissolve d-l3-ethyl-3-(methoxymethoxy)-Sa-gona-1,3, 5 (10-trien-17-one (prepared as described in Example 17, 1.5 g.) in absolute ether and add methyl lithium in ether (50 ml. of 5.1%) and stir for 16 hours. Add aqueous ammonium chloride and wash, dry and evaporate the other layer. Treat the residue with hydroxylamine hydrochloride in pyridine to remove residual starting material and filter through fluosilicate in benzene. Crystallize the residue with petroleum ether to obtain the product (0.360 g.), M.P. 80-82 C.;

LEE; 2.92, 8.65, 9.95 [a] =-10 (c 1, dioxane) Analysis'.-C H O requires (percent): C, 76.70; H, 9.36. Found (percent): C, 76.72; H, 9.60.

1 We claim: 1. A process for the preparation of a 3-(lower) alkoxymethyleneoxy 13 (lower) alkylgona (or 8-isogona)-l,3, 5 ()-triene compound of the formula:

and the A A", A and the A dehydro analogs thereof, wherein R and R are (lower)alkyl, X is R is (lower)alkyl, (lower)alkenyl, (lower)alkynyl or halo (lower)alkylnyl; Y is methylene or hydroxymethylene, the symbol indicates aor fl-configuration, and the broken lines indicate unsaturation in said analogs, which comprises alkylating in an aprotic medium a corresponding aromatic steroidal salt of the formula wherein R, X and Y are as defined above and M is an ion derived from an alkali metal or an alkaline earth metal, with a (lower)alkyl halomethyl ether of the formula wherein hal is chloro, bromo, iodo or fiuoro, until formation of the 3-(lower)alkoxymethyleneoxy group is substantially complete.

2. A process as defined in claim 1 wherein said (lower) alkyl halomethyl ether is chloromethyl methyl ether.

3. A process as defined in claim 1 wherein said R is polycarbon (lower)alkyl.

4. A process as defined in claim 1 wherein said aprotic medium is selected from chloroform, tetrahydrofuran, benzene, dioxane, dimethylformamide, dimethylsulfoxide or 1,2-dimethoxyethane.

5. A process as defined in claim 1 wherein the alkylation is carried out at a temperature of from about C. to about 100 C. for from about 2 hours to about 48 hours.

6. A process as defined in claim 1 where d-3-(methoxymethoxy)estra-1,3,5(10)-trien-17-one is prepared by alkylating the sodium salt of d-estrone in chloroform with chloromethyl methyl ether.

7. A process as defined in claim 6 including the step of ethynylating d-3-(methoxymethoxy) estra-1,3,5 l0) trien-17-one to produce d-3-(methoxymethoxy)-l7a-ethynylestra-1,3,5 l0)-trien-17B-ol.

8. A process as defined in claim 6 including the step of reducing d-3-(methoxymethoxy)estra-1,3,5(10)-trien- 17-one to produce d-3-(methoxymethoxy)estra-1,3,5(10)- trien-17B-ol.

9. A process as defined in claim 1 wherein dl-l3- ethyl-3- (methoXymethoxy)gona-1,3,5(10)-trien 17 one is prepared by alkylating the sodium salt of dl-l3-ethyl- 3-hydroxygona-l,3,5(10)-triene-17-one in tetrahydrofuran with chloromethyl methyl ether.

10. A process as defined in claim 9 including the step of ethynylating dl-l3-ethyl-3-(methoxymethoxy)gona-1,3, 5 (10)-trien-17-0ne to produce dl-l3 ethyl-3-(methoxymethoxy)-l7a-ethynylgona-l,3,5(10)-trien-17fl-ol.

11. A process as defined in claim 9 including the step of reducing dl-l3-ethyl-3-(methoxymethoxy)gona-1,3,5 (10)-trien-l7-one to produce dl-l3-ethyl-3-(methoxymethoxy) gonal ,3,5 10 -trien-17 3-0l.

12. A process as defined in claim 1 wherein dl-3- (methoxymethoxy)estra-1,3,5( 10) ,8-tetraen-l7-one is prepared by alkylating the sodium salt of dl-3-hydroxyestra- 1,3,5 l0),8-tetraen-l7-one in tetrahydrofuran with chloromethyl methyl ether.

13. A process as defined in claim 12 including the step of ethynylating dl-3-(methoxymethoxy)estra-l,3,5 (10) ,8-tetraen-17-one to produce dl-3-(methoxymeth0xy)- l7a-ethynylestra-l,3,5( l0) ,8-tetraen-l7fl-ol.

14. A process as defined in claim 1 wherein dl-l3- ethyl-3-(methoxymethoxy)-8a-gona 1,3,5 (10 trien-17- one is prepared by alkylating the sodium salt of dl-13- ethyl-3-hydroxy-8a-gona-1,3,5 10)-trien-17-one in tetrahydrofuran with chloromethyl methyl ether.

15. A process as defined in claim 14 including the step of ethymylating dl 13 ethyl-3-(methoxymethoxy)-8agona-l,3,5(10)-trien-17-one to produce dl-13-ethyl-3- (methoxymethoxy) l7a-ethynyl-8a-gona 1,3,5(10)- trien-17B-ol.

16. A process as defined in claim 1 wherein d-3- (methoxymethoxy)estra l,3,5(l0),8 tetraen-l7-one is prepared by alkylating the sodium salt of d-3-hydroxyestra-1,3,5(l0),8 tetraen-l7-one in tetrahydrofuran with chloromethyl methyl ether.

17. A process as defined in claim 16 including the step of ethynylating d-3-(methoxymethoxy)estra-l,3,5(10),8- tetraen-17-one to produce d-3-(methoxymethoxy)-17aethynylestra-1,3 ,5 l0 ,8-tetraen-17fl-ol.

18. A process as defined in claim 1 wherein d-3- (methoxymethoxy)-8a-estra-1,3,5(10)-trien-l7-one is prepared by alkylating the sodium salt of d-3-hydroxy-8aestra-1,3,5(10)-trien-17-one in chloroform with chloromethyl methyl ether.

19. A process as defined in claim 18 including the step of ethynylating d-3-(methoxymethoxy)-8a-estra 1,3,5 (10)-trien-17-one to produce d-17a-ethynyl-3-(methoxymethoxy) 8ot-estra-l,3,5 10)-trien-l7/3-ol.

20. A process as defined in claim 1 wherein d-l3-ethyl- 3-(methoxymethoxy)-8a-gona 1,3,5 (10)-trien-l7-one is prepared by alkylating the sodium salt of d-l3-ethyl-3- hydroxy-8a-gona-1,3,5 10)-trien-l7-one in tetrahydrofuran with chloromethylmethyl ether.

21. A process as defined in claim 20 including the step of ethynylating d-l3-ethyl-3-(methoxymethoxy)-8a-gonal,3,5(10)-trien-l7-one to produce d-13-ethyl-17a-ethynyl- 3-(methoxymethoxy) -8a-gona-1,3,5 10 -trien-l7fi-ol.

22. A process as defined in claim 20 including the step of methylating d-l3-ethyl-3-(methoxymethoxy)-8otgona-l,3,5 (10)-17-one to produce d-l3-ethyl-3-(methoxymethoxy)-17a-methyl-8a-gona 1,3,5 10)-trien-17fl-ol.

References Cited UNITED STATES PATENTS 3,060,204 l0/ 1962 Cantrall et al. 26097.5 3,212,971 10/1965 Allais et al. 16765 HENRY A. FRENCH, Primary Examiner U.S. Cl. X.R.

mg UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION 3,5553% Dated January 12, 1971 Harshavadan C. Shah, Reinhardt P. Stein and Invent fls) Herchel Smith Patent No.

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 16, line 60, following "1,3,5(1o)-" insert the word trien- Signed and sealed this 21st day of September 1971.

(SEAL) Attest:

EDWARD M.FLETCI-IER,JR. ROBERT GO'ITSCHALK Attesting Officer Acting Commissioner of Patent 

